[company_age]3.0[/company_age][employees]2-10 employees[/employees][funding]Series A[/funding][description]Resalis Therapeutics is a biopharmaceutical company pioneering the development of non-coding RNA (ncRNA) therapeutics for metabolic disorders, particularly obesity and fatty liver disease. Their unique approach targets a master regulator of key pathways underlying these conditions, offering a potentially transformative treatment option. Resalis leverages its deep understanding of ncRNA biology and lipid metabolism to develop its lead candidate, RES-010, a first-in-class therapy designed to provide durable weight loss and reduce hepatic steatosis. With robust preclinical data supporting its efficacy and safety, Resalis is rapidly advancing RES-010 towards clinical trials for a range of metabolic disorders. The company's commitment to scientific rigor and innovation positions it as a leader in the ncRNA therapeutics field, offering a promising future for patients struggling with these debilitating conditions.[/description][ps]RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.[/ps]